Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.
Vaccine
; 25(44): 7656-63, 2007 Nov 01.
Article
em En
| MEDLINE
| ID: mdl-17913310
ABSTRACT
To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 microg of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 microg of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (> or =4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year. Mean titers of antibody attained, the magnitude of antibody increases and the frequencies of persons with final HAI antibody titers > or =132, > or =164, and > or =1128 were all greater for the high dosage group in both serologic tests, for all groups, and for all vaccine viruses. These increased immune responses should provide increased protection against influenza in the elderly.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vírus da Influenza B
/
Vacinas contra Influenza
/
Glicoproteínas de Hemaglutininação de Vírus da Influenza
/
Vírus da Influenza A Subtipo H1N1
/
Vírus da Influenza A Subtipo H3N2
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos